Method of treatment using a pharmaceutical composition comprising erythrocytes encapsulating a PLP-dependent enzyme and its cofactor
US10046009B2 · kind B2 · utility
2Cited by
7References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 12, 2015 |
| Grant date | Aug 14, 2018 |
| Priority date | — |
| Expiry date | Feb 12, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/124
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a pharmaceutical composition containing a PLP-dependent enzyme and optionally its cofactor, pyridoxal phosphate (PLP), and/or a phosphate or non-phosphate precursor of PLP, its use as a drug, its production method and a therapeutic treatment method related to it. The pharmaceutical composition comprises erythrocytes and a pharmaceutically acceptable vehicle, the erythrocytes encapsulating the PLP-dependent enzyme. The PLP-dependent enzyme may be methioninase, tyrosine phenol-lyase, tyrosine aminotransferase or cystathionine beta-synthase.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.